Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin diseases and skin cancer, is pleased to announce that it will soon begin a GLP toxicology study for DB-007-4, a potential best-in-class, first line topical treatment for inflammatory skin diseases such as acne, atopic dermatitis (AD), and rosacea. Toxicology studies are an essential part of drug development as they help to evaluate the potential safety and toxicity of a drug candidate before it is tested on humans.

Read More

​